Cancel
Brii Biosciences
Brii Biosciences Employees
8 people indexed:
-
Ankang Li
Executive Director, Chief Strategy and Financial Officer
99eu4w.9y@eh6yvue.187 Sign up to see email8d2j5s.8u@6tp3eq0.eyj Sign up to see email -
6w880.ut78u.2wgzy@zu0d3xk.8ue Sign up to see email
-
94f4n.28y6ft98@e81xtuu.th7 Sign up to see email
-
k5j03y2.31.fs9xf@h189ys9.y7y Sign up to see email
-
Karen D. Neuendorff
Chief People Officer and Head of Human Resources
gs00v.9.4268ppqlp2@lq99160.hhy Sign up to see email661sg.0.s4vll4z1t1@hp85831.t6j Sign up to see email -
v994.77v@47a54t8.912 Sign up to see email
-
3kzk0vjp.2zvv1v7y@8kzv945.767 Sign up to see email
-
Zhi Hong
Executive Director, Chairman of the Board and Chief Executive Officer
a74.u7st@2jk10ax.e11 Sign up to see emailv1j.6sxv@49x99j2.ws1 Sign up to see email
Brii Biosciences Company Information
Brii Biosciences is a biotechnology company dedicated to developing therapies for diseases with significant unmet medical needs and large public health burdens, particularly focusing on infectious diseases and central nervous system diseases. The company has a robust pipeline of potential treatment options informed by patient insights and experiences. Brii Biosciences operates in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing, and Shanghai. The company has been listed on the Hong Kong Stock Exchange under the stock code 2137.HK since July 13, 2021. Brii Biosciences successfully closed a US$155 million Series C financing round. Its monoclonal antibodies BRII-196 and BRII-198 have advanced to Phase 3 in the NIH ACTIV-2 trial for ambulatory COVID-19 patients. Additionally, the amubarvimab/romlusevimab combination received approval from the NMPA as the first COVID-19 neutralizing antibody combination therapy in China. Brii Biosciences is also included in the Hang Seng Composite Index and Hong Kong Stock Connect.
Report inaccurate information
Report inaccurate information
